Tagged with ERS

France From Hungary to Poland and now France, Nienke Feenstra has navigated some of Europe’s most complex healthcare landscapes. Today, as GM of Takeda France, she reflects on the country’s scientific strengths, its vital early access frameworks, and the evolving challenges of sustainability and digital transformation, always with patient value at…

France Born from a serendipitous scientific discovery in Montpellier, Abivax has evolved into one of France’s most promising global biotechs. Led by CEO Marc de Garidel, the company is harnessing its pioneering miR-124-based therapy, obefazimod, to redefine treatment possibilities in inflammatory bowel disease through an entirely new, immune-balancing mechanism of action.…

LatAm Arturo De la Rosa, Vice President for Latin America at Gilead Sciences, leverages deep regional experience to navigate healthcare challenges and opportunities across multiple countries. He oversees a dual strategy, sustaining leadership in virology while expanding Gilead’s oncology presence, aiming for it to represent a third of global revenues by…

Brazil Sylvester Feddes, Country President of Novartis Brazil, outlines the country’s rise as a top global market driven by strong public-private healthcare infrastructure and vast unmet needs. With nearly 100 active clinical trials and major launches ahead across cardiovascular-renal-metabolic, immunology, neurology and oncology, Novartis is pairing scientific innovation with new access…

Global Pharma executives are used to navigating complexity, but few periods have tested their judgement like the present. As Brendan Shaw writes, between Washington’s renewed push for “most favoured nation” (MFN) drug pricing, fresh waves of US tariffs, and a volatile global policy mood, the rules of engagement for global pharma…

Brazil As one of Brazil’s leading pharmaceutical powerhouses, CIMED has redefined what it means to be both national and innovative. Built on a fully verticalised model that spans from R&D to direct distribution, the family-owned company has transformed the pharmacy landscape while empowering thousands of independent retailers across the country. Now,…

Global In a pharma industry increasingly squeezed by falling legacy revenues, political pricing crackdowns, and the need to deliver the next wave of science at speed and scale, the right leadership is crucial. Four of the Top 25 global pharma companies – Novo Nordisk (ranked 10th), GSK (12th), Takeda (14th), and…

Denmark When it comes to Denmark’s flourishing local biotech scene, the country is again clearly punching far above its weight. The EU member state has already managed to muster world-class expertise in areas like peptide chemistry and metabolic disorders, anchored by the success stories of homegrown entities that made it big…

Switzerland Marc Gitzinger, CEO and Founder of BioVersys, launched the company from his doctoral research at ETH Zurich on antibiotic resistance. Bioversys began with a tuberculosis programme; today, it owns two proprietary platforms to develop new antibiotics and leads with BV-100, advancing to Phase III for severe hospital infections. Gitzinger also…

Switzerland Kasha Witkos, Senior Vice President and Head of International Business at Alnylam Pharmaceuticals, shares her journey from academic researcher to global biotech leader, driven by personal family experience of chronic disease.  Witkos highlights Alnylam’s pioneering role in delivering RNA interference (RNAi) technology to patients around the world, the company’s global…

Switzerland New Idorsia CEO Srishti Gupta is emphasising “financial discipline” as she looks to turn around the fortunes of one of Europe’s top biotechs.   Challenging Times Gupta, who spent almost two decades at consultancy firm McKinsey, inherits a company that managed to launch three drugs in its first seven years…

China Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the likes of Merck and GSK, and a bold push into competitive therapeutic areas like obesity, the company is staking its…